[FGEN] FibroGen, Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.8 Change: 1.3 (6.67%)
Ext. hours: Change: 0 (0%)

chart FGEN

Refresh chart

Strongest Trends Summary For FGEN

FGEN is in the long-term up 67% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: FibroGen, Inc. discovers, develops, and commercializes drugs for anemia and pulmonary fibrosis. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was founded in 1993 and is headquartered in San Francisco, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 19.29% Sales Growth - Q/Q1.2% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-31.33% ROE-73.92% ROI-45.95%
Current Ratio2.88 Quick Ratio Long Term Debt/Equity0.95 Debt Ratio0.29
Gross Margin Operating Margin-281.76% Net Profit Margin-296.24% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities620 K Cash From Investing Activities4.55 M Cash From Operating Activities-42.19 M Gross Profit
Net Profit-46.37 M Operating Profit-44.72 M Total Assets435.54 M Total Current Assets155.4 M
Total Current Liabilities53.96 M Total Debt111.65 M Total Liabilities250.92 M Total Revenue16.3 M
Technical Data
High 52 week67.25 Low 52 week35.14 Last close35.77 Last change-4.15%
RSI26.06 Average true range2.86 Beta1.53 Volume241.17 K
Simple moving average 20 days-18.87% Simple moving average 50 days-27.97% Simple moving average 200 days-30.35%
Performance Data
Performance Week-1.7% Performance Month-22.48% Performance Quart-38.85% Performance Half-12.05%
Performance Year-32% Performance Year-to-date-22.71% Volatility daily5.57% Volatility weekly12.46%
Volatility monthly25.54% Volatility yearly88.49% Relative Volume223.58% Average Volume843.49 K
New High New Low

News

2019-08-21 16:11:00 | Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis

2019-08-20 16:47:08 | Nabriva NBRV Gains FDA Approval for Pneumonia Drug Xenleta

2019-08-19 17:55:09 | Nabriva NBRV Aims to Resubmit Contepo NDA in Q4

2019-08-15 01:15:29 | Fibrogen Inc FGEN CEO Thomas B Neff Sold $1.8 million of Shares

2019-08-14 09:51:01 | Tilray TLRY Catches Eye: Stock Jumps 8.4%

2019-08-13 09:44:22 | FibroGen NASDAQ:FGEN Has A Pretty Healthy Balance Sheet

2019-08-09 23:07:18 | FibroGen Inc FGEN Q2 2019 Earnings Call Transcript

2019-08-09 17:03:26 | Edited Transcript of FGEN earnings conference call or presentation 8-Aug-19 9:00pm GMT

2019-08-08 20:00:12 | FibroGen FGEN Q2 Earnings and Revenues Top Estimates

2019-08-01 20:39:45 | CORRECTION - FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

2019-08-01 19:24:01 | FibroGen to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

2019-07-30 10:38:02 | Earnings Preview: FibroGen FGEN Q2 Earnings Expected to Decline

2019-07-26 19:15:02 | Fibrogen Inc FGEN CEO Thomas B Neff Sold $1.9 million of Shares

2019-07-24 18:53:26 | Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine NEJM

2019-07-24 18:53:22 | The New England Journal of Medicine NEJM Publishes Roxadustat China Phase 3 Results for the Treatment of Anemia in Chronic Kidney Disease Patients Receiving Dialysis

2019-07-22 07:00:00 | FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis

2019-07-10 06:00:56 | Shareholders Are Thrilled That The FibroGen NASDAQ:FGEN Share Price Increased 165%

2019-06-28 07:00:00 | FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference

2019-06-18 08:04:03 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-06-13 11:20:03 | Here’s What Hedge Funds Think About FibroGen Inc FGEN

2019-06-13 08:04:59 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-06-11 08:06:10 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-06-10 08:12:18 | Can We See Significant Institutional Ownership On The FibroGen, Inc. NASDAQ:FGEN Share Register?

2019-06-10 08:05:09 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-06-10 07:00:00 | FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

2019-06-06 08:04:35 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-06-05 17:00:00 | FibroGen Appoints Suzanne Blaug to Board of Directors

2019-06-04 08:02:42 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-05-16 08:54:12 | Implied Volatility Surging for FibroGen FGEN Stock Options

2019-05-15 13:00:00 | FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm

2019-05-13 06:26:03 | FibroGen Inc FGEN Q1 2019 Earnings Call Transcript

2019-05-10 20:36:00 | FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm

2019-05-10 18:11:18 | Edited Transcript of FGEN earnings conference call or presentation 9-May-19 9:00pm GMT

2019-05-10 14:29:00 | Here's Why FibroGen Fell as Much as 26.6% Today

2019-05-10 12:50:08 | FibroGen News: Why FGEN Stock Is Plummeting Today

2019-05-10 08:00:40 | The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

2019-05-09 20:25:12 | FibroGen FGEN Reports Q1 Loss, Tops Revenue Estimates

2019-05-09 19:19:30 | FibroGen: 1Q Earnings Snapshot

2019-05-09 16:44:50 | FibroGen Reports First Quarter 2019 Financial Results

2019-05-09 16:43:58 | FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program

2019-05-07 08:02:44 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-05-06 17:00:00 | FibroGen to Report First Quarter 2019 Financial Results

2019-05-02 14:34:06 | Zoetis ZTS Earnings Beat Estimates in Q1, Revenues Miss

2019-05-01 10:33:02 | Analysts Estimate FibroGen FGEN to Report a Decline in Earnings: What to Look Out for

2019-05-01 07:39:50 | How Does Investing In FibroGen, Inc. NASDAQ:FGEN Impact The Volatility Of Your Portfolio?

2019-04-30 08:02:12 | See what the IHS Markit Score report has to say about FibroGen Inc.

2019-04-26 09:18:26 | Here’s What Hedge Funds Think About FibroGen Inc FGEN

2019-04-22 00:28:19 | Health Care Digest: Attacking a deadly infant virus, Medicaid's smoking gun and exporting genetic expertise

2019-04-15 07:00:00 | FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

2019-04-10 10:30:02 | Akebia Expands Vadadustat Licensing Deal With Vifor Pharma